Indian pharmaceutical Bravo Grupp's plant in Estonia to cost EUR 3.2 mln

The Indian pharmaceuticals maker Bravo Grupp is about to invest 3.2-3.6 million euros in the construction of a plant in the territory of the Rae municipality to the south of Tallinn and to hire 32 workers in the initial phase, informs LETA/BNS.

"For now the plan is to hire 32 employees, who should be engineers or chemical engineers by training," said Riin Ehin, member of the management board of the Competence Center for Cancer Research (CCCR), which is responsible for launching the plant in Estonia.

Read more business news of Tallinn.

She said that while there could be minor deviations from the original project cost due to climate, the estimated construction cost is from 3.2 to 3.6 million euros.

"Renewal of installations, quality control, training of employees – everything is standardized. While some minor modifications have to be made and maybe some materials substituted, work on the design is under way now in principle," Ehin said.

She added that there was an agreement in principle with the builder, but wouldn't disclose the name of the contractor yet.

The manager said the company was very satisfied with the location, describing proximity to Tallinn Airport and the Tallinn University of Technology as very important factors in choosing the location. She did not rule out the possibility that in the future a second plant will be built in or near Tartu, where the plant was originally planned to be located.

Construction of the plant is planned to start soon and the estimated duration of the works is 18 months.

Bravo Grupp is about to build a 3,000 square meter pharmaceutical plant in the Rae technology park at Juri, a small town situated to the south of Tallinn, to make generic drugs primarily for the Asian and African markets. The final selection of the products will be made in collaboration with the Ministry of Social Affairs and the Estonian Health Insurance Fund.

Bravo Grupp at present has two plants in India, one in Uzbekistan and one in Uganda.

Bravo Grupp has acquired a holding in the Competence Center for Cancer Research (CCCR). According to the Business Register, the shareholders of CCCR are Ibcc Holding AS, AS Cambrex Tallinn, North Estonia Medical Center, Tfs Trial Form, Cemines Estonia OU and AS Kevelt.

Read other news on the city site of Tallinn.

baltic-course
Indianpharmaceutical BravoGrupp'splant
If you notice an error, highlight the text you want and press Ctrl + Enter to report it to the editor
No recommendations yet
Log in ,
to rate and recommend

Comments

Post your comment to communicate and discuss this article.

No results found.